1. Home
  2. AKBA vs NEOG Comparison

AKBA vs NEOG Comparison

Compare AKBA & NEOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKBA
  • NEOG
  • Stock Information
  • Founded
  • AKBA 2007
  • NEOG 1981
  • Country
  • AKBA United States
  • NEOG United States
  • Employees
  • AKBA N/A
  • NEOG N/A
  • Industry
  • AKBA Biotechnology: Pharmaceutical Preparations
  • NEOG Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • AKBA Health Care
  • NEOG Health Care
  • Exchange
  • AKBA Nasdaq
  • NEOG Nasdaq
  • Market Cap
  • AKBA 861.7M
  • NEOG 1.0B
  • IPO Year
  • AKBA 2014
  • NEOG 1989
  • Fundamental
  • Price
  • AKBA $2.95
  • NEOG $5.61
  • Analyst Decision
  • AKBA Strong Buy
  • NEOG Buy
  • Analyst Count
  • AKBA 5
  • NEOG 3
  • Target Price
  • AKBA $6.90
  • NEOG $7.50
  • AVG Volume (30 Days)
  • AKBA 3.9M
  • NEOG 4.6M
  • Earning Date
  • AKBA 11-06-2025
  • NEOG 10-09-2025
  • Dividend Yield
  • AKBA N/A
  • NEOG N/A
  • EPS Growth
  • AKBA N/A
  • NEOG N/A
  • EPS
  • AKBA N/A
  • NEOG N/A
  • Revenue
  • AKBA $203,733,000.00
  • NEOG $894,661,000.00
  • Revenue This Year
  • AKBA $38.23
  • NEOG N/A
  • Revenue Next Year
  • AKBA $38.17
  • NEOG $1.86
  • P/E Ratio
  • AKBA N/A
  • NEOG N/A
  • Revenue Growth
  • AKBA 16.75
  • NEOG N/A
  • 52 Week Low
  • AKBA $1.24
  • NEOG $3.87
  • 52 Week High
  • AKBA $4.08
  • NEOG $17.96
  • Technical
  • Relative Strength Index (RSI)
  • AKBA 40.51
  • NEOG 53.15
  • Support Level
  • AKBA $2.92
  • NEOG $5.52
  • Resistance Level
  • AKBA $3.15
  • NEOG $5.84
  • Average True Range (ATR)
  • AKBA 0.14
  • NEOG 0.22
  • MACD
  • AKBA 0.01
  • NEOG -0.02
  • Stochastic Oscillator
  • AKBA 18.75
  • NEOG 42.59

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About NEOG Neogen Corporation

Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.

Share on Social Networks: